Houslay Miles D
Institute of Pharmaceutical Sciences, 5th Floor Franklin-Wilkins Building, King's College London, London SE1 9NH, UK.
Trends Cancer. 2016 Apr;2(4):163-165. doi: 10.1016/j.trecan.2016.02.007. Epub 2016 Mar 17.
Inhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved blockbuster status in the treatment of penile erectile dysfunction (PED). Their repurposing is currently being proposed to treat certain solid tumours and various other diseases. In cruel irony, however, it appears from recent clinical studies that PDE5 inhibitors may increase the risk of malignant melanoma by negating newly identified brakes on proliferation and metastasis provided by PDE5A.
环磷酸鸟苷（cGMP）降解磷酸二酯酶（PDE）5抑制剂在阴茎勃起功能障碍（PED）的治疗中已成为重磅药物。目前有人提出将其重新用于治疗某些实体肿瘤和其他多种疾病。然而，具有讽刺意味的是，最近的临床研究表明，PDE5抑制剂可能会消除PDE5A对增殖和转移的新发现抑制作用，从而增加恶性黑色素瘤的风险。
